Abstract
Background: The heparan sulfate proteoglycan, syndecan-1 (also known as CD138), is associated with cell proliferation, adhesion, and migration in various types of human malignancies. The role of syndecan-1 in soft tissue tumors is unknown; therefore we examined whether syndecan-1 plays a role in human liposarcoma. Materials and Methods: We performed immunohistochemical analyses of syndecan-1 in 42 liposarcoma cases, including 21 myxoid liposarcoma cases. Recurrence-free survival was estimated by the Kaplan–Meire method. We examined the association between apoptosis and syndecan-1 gene silencing in a human liposarcoma cell line. Results: The proportion of syndecan-1 positive cells (?10%) was significantly associated with unfavorable recurrence-free survival in myxoid liposarcoma patients. There were no significant associations between syndecan-1 expression and prognosis in the other subtypes of liposarcoma. Knockdown of syndecan-1 induced apoptosis and suppression of cell growth in vitro . Conclusion: Syndecan-1 could be a novel prognostic factor for myxoid liposarcoma recurrence and a new therapeutic target for human myxoid liposarcoma.
Highlights
Liposarcoma is the most common soft tissue sarcoma, accounting for at least 20% of all sarcomas in adults (Mack, 1995)
The role of syndecan-1 in soft tissue tumors is unknown; we examined whether syndecan-1 plays a role in human liposarcoma
We examined the association between apoptosis and syndecan-1 gene silencing in a human liposarcoma cell line
Summary
Liposarcoma is the most common soft tissue sarcoma, accounting for at least 20% of all sarcomas in adults (Mack, 1995). Liposarcomas can be divided into three categories: atypical lipomatous tumor/well-differentiated liposarcoma/dedifferentiated liposarcomas, myxoid liposarcomas, and pleomorphic liposarcomas. The most important prognostic factor of atypical lipomatous tumor and dedifferentiated liposarcoma is anatomic location (Fletcher, Bridge, Hogendoorn, & Mertens, 2013). Central location, tumor depth, size and mitotic index have been associated with a worse prognosis (Fletcher et al, 2013). The recurrence rate for atypical lipomatous tumors, dedifferentiated liposarcomas, myxoid liposarcomas and pleomorphic liposarcomas are 63, 14, 41, and 43%, respectively; associated mortalities for these tumors are 11, 31, 28 and 35%, respectively (Weiss & Rao, 1992; Kilpatrick, Doyon, Choong, Sim, & Nascimento, 1996; Henricks, Chu, Goldblum, & Weiss, 1997; Gebhard et al, 2002). The role of syndecan-1 in soft tissue tumors is unknown; we examined whether syndecan-1 plays a role in human liposarcoma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
